Naurex Inc. To Present At Cowen and Company 34th Annual Health Care Conference

EVANSTON, Ill., Feb. 27, 2014 /PRNewswire/ -- Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will present at the Cowen and Company 34^th Annual Health Care Conference on Tuesday, March 4, 2014 at 8:00 a.m. EST. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.

The Cowen and Company 34^th Annual Health Care Conference will be held March 3-5, 2014 at the Boston Marriott Copley Place in Boston, Massachusetts. For more information, visit www.cowen.com/conferences/upcoming-conferences/

About Naurex Inc.
Naurex is a clinical-stage biopharmaceutical company developing products to treat diseases of the central nervous system (CNS). The company’s lead compound, GLYX-13, has shown promising rapid-acting antidepressant activity with excellent safety and no psychomimetic side effects in a Phase 2a clinical study. GLYX-13 is currently in a Phase 2b repeat-dose study as adjunctive therapy for major depressive disorder. Naurex’s 2^nd-generation antidepressant, NRX-1074, is in Phase 1 clinical studies. Naurex’s proprietary platform for the discovery of novel compounds that act at the NMDA receptor to modulate neuronal plasticity has therapeutic potential in a number of CNS indications. For more information, visit www.naurex.com.

SOURCE Naurex, Inc.